The global molecular quality controls market was valued at US$ 0.2 billion in 2023 and is projected to reach US$ 0.3 billion by 2028. This growth represents a resilient compound annual growth rate (CAGR) of 6.6% during the forecast period from 2023 to 2028. The market expansion is primarily driven by the increasing number of accredited clinical laboratories, the growing adoption of third-party quality controls, and rising government funding for genomic research projects.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=82625523
What are the key drivers influencing the growth of the Market?
A primary driver for the molecular quality controls market is the growing preference for personalized medicine. Advances in genomics allow for tailored treatments based on an individual’s genetic profile, increasing the demand for accurate diagnostic tools. The significant reduction in the cost of genome sequencing has further encouraged the development of new technologies and sequencers, making genetic testing more accessible and necessitating rigorous quality control to ensure reliable results.
Additionally, the rising prevalence of infectious diseases and genetic disorders globally fuels the demand for molecular diagnostic tests. The trend toward laboratory accreditation and the implementation of stringent quality standards by government bodies, such as the FDA, compel laboratories to adopt independent or third-party quality controls to validate their testing procedures and identify potential errors, thereby improving diagnostic accuracy.
What are the major restraints limiting the growth of the Market?
Budgetary constraints in clinical laboratories represent a significant restraint. Establishing and maintaining a robust quality control process requires substantial capital investment in dedicated personnel and specialized materials. Because quality control procedures often incur similar costs regardless of test volume, laboratories with lower diagnostic volumes may find the adoption of comprehensive QC practices financially prohibitive.
Furthermore, the high cost associated with advanced molecular diagnostic tests compared to traditional methods can hamper market growth, particularly in developing regions. The infrastructure required for molecular labs, including expensive reagents and sophisticated equipment, can lead to high operational costs that are often passed on to patients, limiting the widespread adoption of these services.
What emerging opportunities are expected to shape the future of the Market?
The rising demand for multi-analyte controls presents a lucrative opportunity for market players. Technological advancements have led to the development of controls that consolidate multiple instrument-specific parameters into a single run. These innovative products allow laboratories to perform quality control for various markers—such as cardiac markers, tumor markers, and different infectious agents—simultaneously, which reduces operational costs and saves time.
Expansion into emerging economies also offers significant growth prospects. Increased funding for genomic research and the rapid development of healthcare infrastructure in regions like Asia-Pacific are driving the need for standardized testing. As more laboratories in these regions seek international accreditation, the demand for high-quality molecular controls is expected to escalate.
What are the critical challenges faced by stakeholders in the Market?
Stakeholders face the challenge of navigating stringent and evolving regulatory requirements for in-vitro diagnostic (IVD) products. In major markets like the US and Europe, regulations are becoming more rigorous, requiring extensive data for premarket submissions such as 510(k) notifications. These unpredictable and demanding requirements can delay product launches and increase the cost of compliance for manufacturers.
Another critical challenge is the lack of mandatory regulations for clinical laboratory accreditation in certain regions. Without a legal mandate, some laboratories may skip comprehensive quality control to reduce costs, which can lead to inconsistencies in test results and challenge the overall growth of the market for standardized control materials.
Who are the leading players operating in the Market?
The global molecular quality controls market is characterized by several dominant players, including F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Bio-Rad Laboratories, Inc. (US), and Thermo Fisher Scientific, Inc. (US). These companies are recognized for their strong product portfolios, ranging from independent controls to instrument-specific materials, and their focus on strategic acquisitions to expand their diagnostic capabilities.
Other significant contributors to the competitive landscape include Abbott Laboratories (US), LGC Limited (UK), Randox Laboratories Ltd. (UK), and QuidelOrtho Corporation (US). Additionally, specialized firms such as ZeptoMetrix, LLC (US), Microbiologics, Inc. (US), and Seegene Inc. (South Korea) play vital roles by offering innovative controls for infectious diseases and advancing the adoption of molecular diagnostics globally.
What are the key segments of the Market based on type, application, and end user?
Based on product type, the market is led by the independent controls segment, which held the highest share in 2022 due to its longer shelf-life and vendor-neutral utility. By analyte type, single-analyte controls dominated the market because of their low risk of cross-reactivity and widespread use in routine hospital assays. Technology-wise, PCR-based controls remain the largest segment, though NGS-based controls are expanding rapidly.
In terms of application, infectious disease diagnostics accounted for the highest share in 2022, driven by the development of advanced assays for various pathogens. For end users, diagnostic laboratories represent the largest segment, supported by an increasing number of accredited facilities and a high volume of laboratory tests performed worldwide. Other key end users include hospitals, IVD manufacturers, and academic research institutes.
Which regions are dominating and emerging in the Market?
North America currently dominates the molecular quality controls market, supported by a well-developed healthcare system, a strong presence of leading manufacturers, and a high volume of molecular testing. The region benefits from established safety standards and significant government investment in medical research, particularly in the United States and Canada.
The Asia-Pacific region is expected to witness the highest growth rate during the forecast period. This upward trend is driven by increasing healthcare needs, a rising focus on the quality of laboratory testing, and strategic developments by key players in countries like China and India. The rapid growth in the number of accredited laboratories in this region is further fueling the demand for molecular quality control products.
Inquire Before Buying-https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=82625523
